Price movement over the last 24 hours
Abbott Laboratories vs State Street Technology Select Sector SPDR ETF — how do they compare? Abbott Laboratories trades at $95.44 (market cap $166.94B), while State Street Technology Select Sector SPDR ETF trades at $180.48. The key difference: Abbott Laboratories pays a 2.63% dividend while State Street Technology Select Sector SPDR ETF pays none, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | XLK | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $198.21 |
52-Week Low | $82.57 | $127.49 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
XLK trades at $183.60, up 1.73% with a neutral technical signal. The ETF has gained 33% year-to-date, making it the top-performing sector SPDR in 2026. Recent news highlights strong tech sector inflows and investor rotation patterns. Technical indicators show mixed signals with RSI readings in neutral territory and key support at $182.
Outlook remains positive given strong sector performance, though risks include potential Fed policy shifts and tech sector volatility. The ETF's low expense ratio and concentrated tech exposure provide competitive advantages, but investors should monitor macroeconomic indicators that could impact tech valuations.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →